Glasdegib

Glasdegib
Clinical data
Synonyms	PF-04449913
Identifiers
	IUPAC name 1-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-3-(4-cyanophenyl)urea;
CAS Number	1095173-27-5;
ChemSpider	28518072;
KEGG	D10636 ;
Chemical and physical data
Formula	C21H22N6O
Molar mass	374.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CC[C@H](C[C@@H]1c2[nH]c3ccccc3n2)NC(=O)Nc4ccc(cc4)C#N;
	InChI InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1; Key:SFNSLLSYNZWZQG-VQIMIIECSA-N;

Glasdegib (PF-04449913) is an experimental cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is overexpressed in many types of cancer. It inhibits smoothened receptor, as do most drug in its class.^[1]

Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib.^[2] Another is a combination trial of glasdenib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia.^[3] The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.^[4] The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.^[5]

References

↑ "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
↑ "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
↑ "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
↑ "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
↑ "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.

[2] "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[3] "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[4] "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[5] "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.